November 11, 2025

GLP-1s are changing the way we treat diabetes and obesity but they are not a cure-all. True progress comes from pairing medication with nutrition, exercise and behavioral support while keeping care affordable. ACHP member plans are leading the way with evidence-based prescribing, lifestyle integration and smart coverage that ensures the right patients get the right treatment at the right time.

Loading...

Taking too long?

Reload document

|

Open in new tab

Download the Infographic

Citations:

1. Institute for Clinical and Economic Review (ICER). “Obesity Draft Evidence Report.” September 24, 2025. https://icer.org/wp-content/uploads/2025/09/ICER_Obesity_Draft-Report_For-Publication_090925.pdf.

2. 5.eClinicalMedicine (The Lancet Discovery Science). “Healthy weight loss maintenance with exercise, GLP-1 receptor agonist …” 2024. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2824%2900054-3/fulltext.

3. Prime Therapeutics. “GLP-1 therapy to treat obesity among members without diabetes: three-year persistence.” 2024. https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence.

4. American Diabetes Association. “Sustained Weight and Metabolic Health following GLP-1 Deprescription (DeRx).” Diabetes. 2021 Supplement. https://diabetesjournals.org/diabetes/article/74/Supplement_1/2021-LB/159878/2021-LB-Sustained-Weight-and-Metabolic-Health.

5. Alhiary, R., et al. “Patents and regulatory exclusivities on GLP-1 receptor agonists.” National Library of Medicine. August 15, 2023. https://achp.pub/NLM-GLP1.

6. Tolbert, J., & Simpson, M. “Medicaid coverage of and spending on GLP-1s.” KFF. May 9, 2024. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/.

7. Rodriguez PJ, Zhang V, Gratzl S, et al. “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025. doi:10.1001/jamanetworkopen.2024.57349.

Comprehensive Obesity Care, Not Just GLP-1s

Citations:

1. Institute for Clinical and Economic Review (ICER). “Obesity Draft Evidence Report.” September 24, 2025. https://icer.org/wp-content/uploads/2025/09/ICER_Obesity_Draft-Report_For-Publication_090925.pdf.

2. 5.eClinicalMedicine (The Lancet Discovery Science). “Healthy weight loss maintenance with exercise, GLP-1 receptor agonist …” 2024. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2824%2900054-3/fulltext.

3. Prime Therapeutics. “GLP-1 therapy to treat obesity among members without diabetes: three-year persistence.” 2024. https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence.

4. American Diabetes Association. “Sustained Weight and Metabolic Health following GLP-1 Deprescription (DeRx).” Diabetes. 2021 Supplement. https://diabetesjournals.org/diabetes/article/74/Supplement_1/2021-LB/159878/2021-LB-Sustained-Weight-and-Metabolic-Health.

5. Alhiary, R., et al. “Patents and regulatory exclusivities on GLP-1 receptor agonists.” National Library of Medicine. August 15, 2023. https://achp.pub/NLM-GLP1.

6. Tolbert, J., & Simpson, M. “Medicaid coverage of and spending on GLP-1s.” KFF. May 9, 2024. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/.

7. Rodriguez PJ, Zhang V, Gratzl S, et al. “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025. doi:10.1001/jamanetworkopen.2024.57349.

New from ACHP

Citations:

1. Institute for Clinical and Economic Review (ICER). “Obesity Draft Evidence Report.” September 24, 2025. https://icer.org/wp-content/uploads/2025/09/ICER_Obesity_Draft-Report_For-Publication_090925.pdf.

2. 5.eClinicalMedicine (The Lancet Discovery Science). “Healthy weight loss maintenance with exercise, GLP-1 receptor agonist …” 2024. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2824%2900054-3/fulltext.

3. Prime Therapeutics. “GLP-1 therapy to treat obesity among members without diabetes: three-year persistence.” 2024. https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence.

4. American Diabetes Association. “Sustained Weight and Metabolic Health following GLP-1 Deprescription (DeRx).” Diabetes. 2021 Supplement. https://diabetesjournals.org/diabetes/article/74/Supplement_1/2021-LB/159878/2021-LB-Sustained-Weight-and-Metabolic-Health.

5. Alhiary, R., et al. “Patents and regulatory exclusivities on GLP-1 receptor agonists.” National Library of Medicine. August 15, 2023. https://achp.pub/NLM-GLP1.

6. Tolbert, J., & Simpson, M. “Medicaid coverage of and spending on GLP-1s.” KFF. May 9, 2024. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/.

7. Rodriguez PJ, Zhang V, Gratzl S, et al. “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025. doi:10.1001/jamanetworkopen.2024.57349.

New from ACHP

7. Rodriguez PJ, Zhang V, Gratzl S, et al. “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025. doi:10.1001/jamanetworkopen.2024.57349.